Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jul;60(1):104–106. doi: 10.1038/bjc.1989.230

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.

D J Kerr 1, T Maughan 1, E Newlands 1, G Rustin 1, N M Bleehen 1, C Lewis 1, S B Kaye 1
PMCID: PMC2247346  PMID: 2803908

Abstract

Flavone acetic acid (FAA), 8.6 gm-2 has been administered by 6h intravenous infusion to 19 patients with advanced colorectal carcinoma and 15 patients with advanced malignant melanoma. The drug associated toxicity was generally mild and as predicted from the phase I study. No responses were seen in either disease.

Full text

PDF
104

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bissery M. C., Valeriote F. A., Chabot G. G., Crissman J. D., Yost C., Corbett T. H. Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo. Cancer Res. 1988 Mar 1;48(5):1279–1285. [PubMed] [Google Scholar]
  2. Corbett T. H., Bissery M. C., Wozniak A., Plowman J., Polin L., Tapazoglou E., Dieckman J., Valeriote F. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs. 1986;4(3):207–220. doi: 10.1007/BF00179586. [DOI] [PubMed] [Google Scholar]
  3. Davis H. P., Newlands E. S., Allain T., Hegde U. Immune thrombocytopenia caused by flavone-8-acetic acid. Lancet. 1988 Feb 20;1(8582):412–412. doi: 10.1016/s0140-6736(88)91201-9. [DOI] [PubMed] [Google Scholar]
  4. Evelhoch J. L., Bissery M. C., Chabot G. G., Simpson N. E., McCoy C. L., Heilbrun L. K., Corbett T. H. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 1988 Sep 1;48(17):4749–4755. [PubMed] [Google Scholar]
  5. Hornung R. L., Young H. A., Urba W. J., Wiltrout R. H. Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta. J Natl Cancer Inst. 1988 Oct 5;80(15):1226–1231. doi: 10.1093/jnci/80.15.1226. [DOI] [PubMed] [Google Scholar]
  6. Kerr D. J., Kaye S. B., Cassidy J., Bradley C., Rankin E. M., Adams L., Setanoians A., Young T., Forrest G., Soukop M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res. 1987 Dec 15;47(24 Pt 1):6776–6781. [PubMed] [Google Scholar]
  7. Kerr D. J., Kaye S. B., Graham J., Cassidy J., Harding M., Setanoians A., McGrath J. C., Vezin W. R., Cunningham D., Forrest G. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res. 1986 Jun;46(6):3142–3146. [PubMed] [Google Scholar]
  8. Smith G. P., Calveley S. B., Smith M. J., Baguley B. C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol. 1987 Aug;23(8):1209–1211. doi: 10.1016/0277-5379(87)90157-x. [DOI] [PubMed] [Google Scholar]
  9. Zaharko D. S., Grieshaber C. K., Plowman J., Cradock J. C. Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors. Cancer Treat Rep. 1986 Dec;70(12):1415–1421. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES